Evidence map›Paper›PMID 23286849›Full record

ReviewLiver international : official journal of the International Association for the Study of the Liver2013

Best strategies for global HCV eradication.

Liesl M Hagan, Raymond F Schinazi

Registry-linked trialAbstract readReview
In one paragraph

Review in Liver international : official journal of the International Association for the Study of the Liver, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05071261 (A Communication-Based Study Focused on Assessing and Improving Hepatitis C Screening Rates, As Well As Treatment Rates in Arizona as a Step Towards Disease Eradication), which is not on this map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05071261 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

A Communication-Based Study Focused on Assessing and Improving Hepatitis C Screening Rates, As Well As Treatment Rates in Arizona as a Step Towards Disease Eradication

TypeobservationalSponsorLiver Institute PLLCRan2024 to 2030Enrolled112,136ConditionsHepatitis C Virus InfectionArmsHepatitis C Virus Screening
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Liesl M HaganCenter for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, GA 30033, USA. lhagan2@emory.edu
Raymond F Schinazi

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
NIAID NIH HHS 2P30-AI-050409NIAID NIH HHS P30 AI050409
6 · The paper itself

Abstract

Worldwide eradication of hepatitis C virus (HCV) is possible through a combination of prevention education, universal clinical and targeted community screening, effective linkage to care and treatment with promising new direct-acting antiviral drug regimens. Universal screening should be offered in all healthcare visits, and parallel community screening efforts should prioritize high-prevalence, high-transmission populations including injection drug users, prison inmates and those with HIV/HCV co-infection. Increasing awareness of HCV infection through screening, improving treatment uptake and cure rates by providing linkage to care and more effective treatment, and ultimately combining education efforts with vaccination campaigns to prevent transmission and reinfection can slow and eventually stop the 'silent epidemic'.

Indexed as

Global HealthMass ScreeningRisk Reduction BehaviorViral Hepatitis VaccinesAntiviral AgentsDelivery of Health Care, IntegratedHealth EducationHealth Knowledge, Attitudes, PracticeHealth Services AccessibilityHepatitis C, ChronicHumansPatient Acceptance of Health CarePredictive Value of TestsPublic OpinionRisk AssessmentRisk FactorsAntiviral AgentsViral Hepatitis Vaccines

Identifiers

PMID23286849
PMCPMC4110680

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.